(Q40323824)

19 September 2017

title

Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells (English)

1 reference

19 September 2017

1 reference

Oliver Treeck

1 reference

19 September 2017

Birgit Wackwitz

series ordinal

1 reference

19 September 2017

Ulrike Haus

series ordinal

1 reference

19 September 2017

Olaf Ortmann

series ordinal

1 reference

19 September 2017

language of work or name

English

0 references

publication date

26 January 2006

1 reference

19 September 2017

1 reference

19 September 2017

volume

102

1 reference

19 September 2017

1 reference

19 September 2017

page(s)

292-299

1 reference

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.019

SDZ RAD, a new rapamycin derivative: synergism with cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.019

Targeting mTOR signaling for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.019

The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.019

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.019

AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.019

Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.019

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.019

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.019

Quantitative real-time PCR method for detection of B-lymphocyte monoclonality by comparison of kappa and lambda immunoglobulin light chain expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.019

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.019

Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.019

Tamoxifen as a risk factor for endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.019

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.019

AKT involvement in cisplatin chemoresistance of human uterine cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.019

Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.019

Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.12.019

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2005.12.019

1 reference

19 September 2017

1 reference